Semaglutide tied to slower epigenetic aging in HIV trial

Clinical takeaway: These data add to the case that semaglutide benefits may reach beyond weight and glucose. The aging signal needs confirmation in prospective trials.

GLP-1 receptor agonists have drawn interest as possible anti-aging agents, but supportive evidence from randomized human trials hasn't been available. This analysis asked whether semaglutide affects biological aging measured by DNA methylation clocks, which estimate how fast a person's cells are aging relative to calendar time.

Semaglutide was linked to slower epigenetic aging, with the clearest effects on clocks that predict mortality and morbidity risk. On a measure of the overall pace of aging, the drug was associated with a 9% slower annual rate versus placebo across the 32-week trial. A separate analysis using an independent framework confirmed slower aging on two versions of a widely used mortality-prediction clock. The cohort was adults with HIV-associated lipohypertrophy, a group that faces issues around visceral fat, chronic inflammation, and accelerated aging.

First-generation clocks that mainly track chronological age showed directionally consistent but mostly non-significant changes. Clocks built to capture resilience or to separate causal from non-causal aging showed no clear treatment effect.

Across a panel of organ-system clocks, semaglutide was associated with slower aging in the inflammation, brain, metabolic, blood, heart, kidney, and liver measures, while lung, musculoskeletal, immune, and hormone clocks did not reach significance. These system clocks are derived from blood methylation, so they are indirect proxies for organ aging rather than direct evidence of tissue change.

This was a post hoc, exploratory analysis of an already-completed phase 2b trial. Of 108 randomized participants, 84 had paired blood samples for epigenetic profiling at baseline and 32 weeks. The cohort was middle-aged, virally suppressed, and obese, with men over-represented in the semaglutide arm; models adjusted for sex, BMI, and two inflammatory markers.

Larger trials need to test whether GLP-1 drugs actually slow aging in people without HIV disease. "We are not saying that semaglutide reverses aging or makes people younger," said Michael Corley, PhD, of the University of California San Diego School of Medicine. "What we are seeing is a signal that it may slow some of the biological processes associated with aging."

Source: Corley MJ. Nat Commun. 2026 Jun 2. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy